BOSTON, Nov. 10, 2008 (GLOBE NEWSWIRE) -- Generex Biotechnology (Nasdaq:GNBT) announces that Scimitar Equity, LLC issues a review of Generex Biotechnology Corporation, entitled, "Breaking-out the Sum of the Parts: Antigen Express' Novel Cancer Immunotherapy Emerges as a Jewel."
Investors in Generex Biotechnology (Nasdaq:GNBT) now have two (2) product pipelines from which increased value could be realized. Complementing GNBT's emerging diabetes franchise, Antigen Express' technology has been applied to an outstanding set of immunotherapeutic clinical candidates. Antigen Express' current product focus is on breast, prostate and other novel cancer vaccines in addition to product candidates in avian influenza and other prophylaxis vaccines as well as certain diagnostic products, that are also advancing towards commercialism. This small subsidiary has built an impressive portfolio of product candidates.
Generex Biotechnology Corporation's Antigen Express President, Eric von Hofe, PhD will present a corporate overview at the upcoming Rodman & Renshaw 10th Annual Healthcare Conference on Monday, November 10, 2008, at 10:20 a.m. ET at the New York Palace Hotel in New York, NY.
This review is available at website: www.scimitarequity.com.
Antigen Express is a platform and product-based company developing proprietary vaccine formulations for large, unmet medical needs. The focus is on stimulating critical members of the immune response, known as T helper cells. The technology allows for antigen-specific stimulation or suppression of a T-helper response to virtually any antigen of known pathogenic potential. Antigen Express is building a deep pipeline of therapeutics aimed at a variety of major diseases, including cancer, infectious diseases and autoimmune-based syndromes. Antigen Express therapies are based on highly selective modulation of the immune response, in contrast to most current immunomodulation strategies that are in general non-specific. This lack of specificity is the prime source for unwanted side effects. The therapies developed at Antigen Express intervene at the critical stage of antigen presentation to modulate the immune response. This targeted approach results in a potent up or down regulation of critical members of the immune system. The technologies developed at Antigen Express are novel and highly complementary to existing approaches of immune modification. Antigen Express is uniquely positioned to develop partnerships where Antigen Express technology enhances or augments the corporate partners' technology or product portfolios. For more information, visit the Antigen Express website at http://www.antigenexpress.com.
Generex Biotechnology Corporation is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. For more information, visit the Generex website at http://www.generex.com.
The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831
Scimitar Equity, LLC provides sponsored equity research of emerging healthcare companies for the investing communities. We certify that all the views expressed in this review, accurately reflect our personal views about Generex Biotechnology Corporation (Nasdaq:GNBT) and its or their securities. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views contained in this review and we will not have any investment banking relationships or personal investment in any sponsored company. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. Scimitar was paid for preparing this review. This analysis and review does not have regard to the specific investment objectives, financial situation and the information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Any opinions expressed are statements of our own judgment as of the date of publication and are subject to change without notice. Please read all our important disclosures.